MediciNova Announces MN-001 (tipelukast) Research Collaboration with The Juntendo University School of Medicine in Tokyo, Japan
MediciNova, Inc. (MNOV) announced a research collaboration with Juntendo University to study the effects of MN-001 (tipelukast) on lipid metabolism and metabolic syndrome. Led by Dr. Takashi Mitsui, the research aims to deepen understanding of MN-001's mechanisms, which have shown benefits in reducing triglycerides and improving lipid profiles in previous clinical trials, particularly for patients with type 2 diabetes. MediciNova is focused on developing therapies for inflammatory and fibrotic diseases, with MN-001 being a key component in their clinical pipeline.
- Initiation of a research collaboration with Juntendo University to evaluate MN-001's effects on lipid metabolism.
- Previous clinical trials indicated MN-001 effectively reduces triglyceride levels and improves HDL-C and LDL profiles.
- Targeting a critical area in metabolic syndrome and potential benefits for patients with type 2 diabetes.
- None.
LA JOLLA, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will initiate a comprehensive research collaboration with Juntendo University, School of Medicine (2-1-1 Hongo, Bunkyo-Ku, Tokyo, Japan) to evaluate the mechanism of the action of MN-001 (tipelukast) on lipid metabolism and metabolic syndrome.
The lead collaborator is Takashi Mitsui MD, Ph.D., professor and the chair of the Department of Laboratory Medicine, a known leading expert on lipid metabolism who specializes in dyslipidemia and metabolic syndrome.
Kazuko Matsuda, MD, Ph.D., MPH, Chief Medical Officer of MediciNova, Inc, commented, “MN 001 is a novel orally-administered compound with multiple mechanisms, and its anti-fibrotic and anti-inflammatory effects have been observed in multiple animal models studies. It has also been observed to reduce serum triglyceride levels for patients with high serum triglycerides in multiple clinical trials conducted previously. In the phase 2 trial in NASH/NAFLD patients with hypertriglyceridemia, MN-001 (tipelukast) reduced serum triglycerides, increased high-density lipoproteins (HDL-C), and reduced low-density lipoproteins (LDL) during the 12-week treatment period. Furthermore, the improvements in the serum lipid profile were more significant in the patients with type 2 diabetes/prediabetes. We believe this research collaboration will provide new insights into the mechanism of action of MN-001 in the lipid metabolism and metabolic syndrome field and identify the conditions that would benefit from MN-001 treatment.”
About MN-001 (tipelukast)
MN-001 (tipelukast) is a novel, orally bioavailable, small molecule compound thought to exert its effects through several mechanisms to produce its anti-inflammatory and anti-fibrotic activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDE) (mainly 3 and 4), and inhibition of 5-lipoxygenase (5-LO). The 5-LO/LT pathway has been postulated as a pathogenic factor in fibrosis development, and MN-001's inhibitory effect on 5-LO and the 5-LO/LT pathway is a novel approach to treat fibrosis. MN-001 has been shown to down-regulate expression of genes that promote fibrosis including LOXL2, Collagen Type 1 and TIMP-1. MN-001 has also been shown to down-regulate expression of genes that promote inflammation including CCR2 and MCP-1. In addition, MN-001 was found to inhibit triglyceride synthesis in hepatocytes by inhibiting arachidonic acid uptake.
About MediciNova
MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) was studied in a Phase 2 trial in patients at risk of developing acute respiratory distress syndrome (ARDS) and is also being evaluated in Phase 2 trials in glioblastoma, and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and is in preparation for a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD). MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants.
Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166, MN-001, MN-221, and MN-029. These forward-looking statements may be preceded by, followed by or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166, MN-001, MN-221, and MN-029 and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2021 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.
INVESTOR CONTACT:
Geoff O'Brien
Vice President
MediciNova, Inc.
info@medicinova.com
FAQ
What is the latest development for MediciNova (MNOV) regarding MN-001?
How has MN-001 (tipelukast) performed in previous clinical trials?
Who is leading the research collaboration for MN-001 at Juntendo University?